The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Baker McKenzie

HOLBEINSTRASSE 30, 8034 ZURICH, SWITZERLAND
Tel:
Work +41 44 384 14 14
Fax:
Fax +41 44 384 12 84
Email:
Web:
www.bakermckenzie.com

Ra Dr Peter Reinert

Tel:
Work +41 44 384 13 41
Email:
Web:
www.bakermckenzie.com/en/people/r/reinert-peter
Baker McKenzie

Work Department

Please visit https://www.bakermckenzie.com/en/people/r/reinert-peter to learn more about our lawyers.


Switzerland

Employment

Within: Leading individuals

Peter Reinert - Baker McKenzie

Within: Employment

Baker McKenzie's major strength is the ability to work on international employment matters and 'include colleagues from specific jurisdictions who have the required knowledge'. Employment contracts, benefit plans, restructurings and litigation, as well as hirings, terminations and global removals form the key areas of expertise. Associate Serge Pannatier is defending Becton Dickinson against a female employee's discrimination damages claim valued at £1.7m. Practice lead Peter Reinert is recommended for his 'sufficient risk analysis, which enables the client to make the right decision'.

[back to top]

Healthcare and life sciences

Within: Healthcare and life sciences

Best known for cross-border transactions and compliance work, Baker McKenzie also handles employment, corporate, intellectual property, tax and real estate matters for a broad spectrum of private and public healthcare and pharmaceutical clients, as well as sector-related tech companies and insurers. Peter Reinert acted as regulatory adviser to Servier during its acquisition of Shire's oncology business, while Anne-Catherine Hahn assisted a Swiss pharmaceutical company with the implementation of its global anti-bribery programme in more than 20 jurisdictions. The team advises Abbott on the management and enforcement of its trade marks in Switzerland.

[back to top]

Leading firms: German-speaking Switzerland

Within: Leading firms: German-speaking Switzerland

Baker McKenzie is highly regarded for its employment, intellectual property, sports, insolvency and real estate practices. Peter Reinert, Lukas Glanzmann, Michael Treis and Martin Furrer are the key contacts in these areas.

[back to top]


Back to index

Legal Developments by:
Baker McKenzie

  • The New Turkish Code of Obligations: Important Changes for Leases of Residential & Business Premises

    For decades, the primary Turkish laws governing leases of residential and business premises have been the Law on Leasing Real Property dated May 27, 1955 (the “Lease Law”) and the Turkish Code of Obligations No. 818 dated April 22, 1926 (the “Obligations Code”). Both of these laws, however, will be repealed and replaced with the new Turkish Code of Obligations No. 6098 dated January 11, 2011 (the “New Obligations Code”), which will enter into force on July 7, 2012.
    - Esin Attorney Partnership

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Bär & Karrer Advises Acushnet on the Acquisition of KJUS

    Acushnet Holdings Corp., the worldwide leader in the design, development, manufacture and distribution of golf equipment and wear, has announced the acquisition of KJUS, a Swiss-based ski and golf sportswear company.
  • Bär & Karrer Advised Cembra Money Bank on the Financing of the Acquisition of cashgate

    Cembra Money Bank has agreed to acquire cashgate. The purchase price for the acquisition of cashgate and the refinancing of cashgate's loan portfolio is partly backed by a bridge facility and is financed and refinanced by the sale of treasury shares (gross proceeds of CHF 112.8 million) in an accelerated bookbuilding, the placement of CHF 150 million perpetual additional Tier 1 bonds and CHF 250 million net share settled convertible bonds.
  • Bär & Karrer Successfully Represents PNK Group Company in SCAI-Arbitration

    Bär & Karrer successfully represented a company acting under the trademark of PNK Group, a major developer of industrial facilities in Russia, against a Western European concrete plant engineering and manufacturing company in a SCAI-arbitration concerning the delivery of (defective) equipment. After full-fledged proceedings including a hearing with several technical experts, the client was awarded partial rescission of the contract (as requested) with returning of certain defective equipment against refund of its cost, a substantial price reduction with regard to the rest of the equipment, as well as a contractual penalty payment and reimbursement for 75% of all legal costs. Team members were Matthew Reiter and Désirée Schreyer (both arbitration).
  • Bär & Karrer Advises Zurich on its Investment in autoSense

    Zurich Insurance Company Ltd (Zurich) invests in the Swiss start-up autoSense. Zurich will further develop autoSense's business together with Swisscom and Amag. autoSense operates a digital service portal which connects vehicles through an app and provides real-time information and services to car owners.
  • Bär & Karrer Advises Swedish Orphan Biovitrum AB in the Acquisition of emapalumab

    Swedish Orphan Biovitrum AB, an international specialty biopharmaceutical company listed in Sweden, agreed to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition supersedes the previously announced exclusive licence agreement with Novimmune. In addition, Sobi agreed with Novimmune on options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology. The transaction value is CHF 515 million, of which CHF 400 million was previously committed in the exclusive license agreement for emapalumab.
  • Bär & Karrer Advises Patinex and BZ Bank on the Sale of NovImmune to Light Chain Bioscicence

    Light Chain Bioscience AG, a Swiss biotech company, agreed to purchase all shares in NovImmune SA, a company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune related disorders and cancer. Patinex and BZ Bank are the selling majority shareholders of NovImmune.
  • Bär & Karrer Awarded "Law Firm of the Year - Switzerland" at the Citywealth Magic Circle Awards 201

    Bär & Karrer is pleased to announce that it has received the award “Law Firm of the Year - Switzerland” at the Citywealth Magic Circle Awards in London. This award recognizes Bär & Karrer as the Swiss law firm with the best private client team.
  • Bär & Karrer Advises Ashcroft on the Acquisition of RĂĽeger Holding

    Ashcroft Inc., headquartered in Stratford, CT, USA, a subsidiary of Tokyo Stock Exchange listed Nagano Keiki Co., Ltd, has announced the completion of the acquisition of Swiss-based RĂĽeger Holding SA (RĂĽeger) and Dutch-based STIKO Meetapparentenfabriek B.V. (Stiko), both manufacturers of specialty temperature and pressure measurement products, from their previous owners, Bernard and Jean-Marc RĂĽeger.
  • Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

    Click here for more information.
  • Bär & Karrer Advises B3i in its Current Equity Funding Round

    Industry-led InsurTech B3i Services AG successfully raised additional funds from current shareholders and new investors to further develop and grow its blockchain-based insurance transaction platform. B3i was founded in October 2016 as an insurance industry consortium which then formed B3i Services AG as an independent company. The shareholder group includes some of the world's largest insurers and reinsurers from across Europe, the Americas, and Asia. B3i intends to further expand its shareholder base over the next several months.